12788169

Source:http://linkedlifedata.com/resource/pubmed/id/12788169

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0011900, umls-concept:C0178602, umls-concept:C0206012, umls-concept:C0220644, umls-concept:C0851346, umls-concept:C1096776, umls-concept:C1274040, umls-concept:C1511341, umls-concept:C1521725, umls-concept:C1546857
pubmed:issue	3
pubmed:dateCreated	2003-6-5
pubmed:abstractText	The identification of risk factors is required for risk-adapted treatment strategies in the treatment of Hodgkin's disease. To assess the influence of bulky disease at diagnosis as compared with other risk factors on event-free survival (EFS) in pediatric Hodgkin's disease such as stage, B-symptoms, number of involved lymph node regions, histology, and remission status after chemotherapy, we analyzed the outcome of 552 patients treated with a risk-adapted treatment strategy consisting of OPPA(OEPA)/COPP (vincristine, procarbazine, etoposide, prednisone, adriamycin, cyclophosphamide) and involved-field radiotherapy.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7603616
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin, http://linkedlifedata.com/resource/pubmed/chemical/Prednisone, http://linkedlifedata.com/resource/pubmed/chemical/Procarbazine, http://linkedlifedata.com/resource/pubmed/chemical/Vincristine
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0360-3016
pubmed:author	pubmed-author:DieckmannKarinK, pubmed-author:HeinzlHaraldH, pubmed-author:HofmannJohannesJ, pubmed-author:PötterRichardR, pubmed-author:Pediatric Cooperative Hodgkin Disease Study Group of the GPOH, pubmed-author:SchellongGüntherG, pubmed-author:WagnerWolfgangW
pubmed:issnType	Print
pubmed:day	1
pubmed:volume	56
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	644-52
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12788169-Adolescent, pubmed-meshheading:12788169-Analysis of Variance, pubmed-meshheading:12788169-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12788169-Child, pubmed-meshheading:12788169-Child, Preschool, pubmed-meshheading:12788169-Combined Modality Therapy, pubmed-meshheading:12788169-Cyclophosphamide, pubmed-meshheading:12788169-Disease Progression, pubmed-meshheading:12788169-Disease-Free Survival, pubmed-meshheading:12788169-Doxorubicin, pubmed-meshheading:12788169-Female, pubmed-meshheading:12788169-Hodgkin Disease, pubmed-meshheading:12788169-Humans, pubmed-meshheading:12788169-Lymphatic Metastasis, pubmed-meshheading:12788169-Male, pubmed-meshheading:12788169-Mediastinal Neoplasms, pubmed-meshheading:12788169-Neoplasm Staging, pubmed-meshheading:12788169-Prednisone, pubmed-meshheading:12788169-Procarbazine, pubmed-meshheading:12788169-Proportional Hazards Models, pubmed-meshheading:12788169-Radiotherapy Dosage, pubmed-meshheading:12788169-Recurrence, pubmed-meshheading:12788169-Remission Induction, pubmed-meshheading:12788169-Retrospective Studies, pubmed-meshheading:12788169-Risk Factors, pubmed-meshheading:12788169-Treatment Outcome, pubmed-meshheading:12788169-Vincristine
pubmed:year	2003
pubmed:articleTitle	Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
pubmed:affiliation	Department of Radiotherapy and Radiobiology, University of Vienna, General Hospital Vienna, Vienna, Austria. karin.dieckmann@akhwien.at
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study